Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT)

RECOMMENDED

Lung Cancer

The Value of ¹⁸F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Clin Lung Cancer

Vekens K, Everaert H, Neyns B, Ilsen B, Decoster L

doi: 10.1016/j.cllc.2021.03.001

RECOMMENDED

Lung Cancer

A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study)

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Clin Lung Cancer

Shiraishi Y, Hakozaki T, Nomura S, Kataoka T, Tanaka K, Miura S, Sekino Y, Ando M, Horinouchi H, Ohe Y, Okamoto I

doi: 10.1016/j.cllc.2021.10.012

RECOMMENDED

Lung Cancer

Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Clin Lung Cancer.

Velcheti V, Chandwani S, Chen X, Piperdi B, Burke T

doi: 10.1016/j.cllc.2020.02.023.

RECOMMENDED

Lung Cancer

Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial

★ 2 Recommended by Dr Martin Frey, Faculty Member

Lung Cancer

Park K, Özgüroğlu M, Vansteenkiste J, Spigel D, Yang JC, Bajars M, Ruisi M, Manitz J, Barlesi F

doi: 10.1016/j.lungcan.2021.01.026

COMMENTED

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

Lancet Respir Med.

Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M

doi: 10.1016/S2213-

RECOMMENDED

Lung Cancer

Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer.

Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Schütt P, Steger F, Brückl WM, Christoph DC

doi: 10.1016/j.lungcan.2020.10.006.Visit the original publication at ncbi.nlm.nih.gov

RECOMMENDED

Lung Cancer

Perioperative course and quality of life in a prospective randomized multicenter phase III trial, comparing standard lobectomy versus anatomical segmentectomy in patients with non-small cell lung cancer up to 2 cm, stage IA (7th edition of TNM staging system)

★ 2 Recommended by Alexander Meisel, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer.

Stamatis G, Leschber G, Schwarz B, Brintrup DL, Ose C, Weinreich G, Passlick B, Hecker E, Kugler C, Dienemann H, Krbek T, Eggeling S, Hatz R, Müller MR, Weder W, Aigner C, Jöckel KH

doi: 10.1016/j.lungcan.2019.09.021.

RECOMMENDED

Lung Cancer

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lancet

Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk HM, Cicin I, Bentsion D, Gladkov O, Clingan P, Sriuranpong V, Rizvi N, Gao B, Li S, Lee S, McGuire K, Chen CI, Makharadze T, Paydas S, Nechaeva M, Seebach F, Weinreich DM, Yancopoulos GD, Gullo G, Lowy I, Rietschel P

doi: 10.1016/S0140-6736(21)00228-2

RECOMMENDED

Lung Cancer

Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Clin Lung Cancer

Mountzios G, de Toma A, Economopoulou P, Friedlaender A, Banini M, Lo Russo G, Baxevanos P, Roila F, Banna GL, Christopoulou A, Jimenez B, Collazo-Lorduy A, Linardou H, Calles A, Galetta D, Addeo A, Camerini A, Pizzutilo P, Kosmidis P, Garassino MC, Proto C, Signorelli D, Metro G

doi: 10.1016/j.cllc.2020.09.017

Related content

The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression

A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study)

Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival

Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)

Perioperative course and quality of life in a prospective randomized multicenter phase III trial, comparing standard lobectomy versus anatomical segmentectomy in patients with non-small cell lung cancer up to 2 cm, stage IA (7th edition of TNM staging system)

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy

The Value of ¹⁸F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression

Perioperative course and quality of life in a prospective randomized multicenter phase III trial, comparing standard lobectomy versus anatomical segmentectomy in patients with non-small cell lung cancer up to 2 cm, stage IA (7th edition of TNM staging system)